2387-08-8 Usage
Description
4,5-Dichloro-2-methylaniline is an organic compound with the molecular formula C7H8Cl2N. It is a derivative of aniline, featuring a methyl group at the 2nd position and two chlorine atoms at the 4th and 5th positions. 4,5-Dichloro-2-methylaniline is known for its chemical reactivity and is commonly utilized as a building block in the synthesis of various pharmaceuticals and chemical products.
Uses
Used in Pharmaceutical Industry:
4,5-Dichloro-2-methylaniline is used as a building block reagent for the synthesis of various drug analogues and pharmaceutical goods. Its unique chemical structure allows it to be a valuable component in the development of new medications, potentially contributing to the treatment of various diseases and health conditions.
Used in Chemical Synthesis:
In the chemical industry, 4,5-Dichloro-2-methylaniline is employed as an intermediate in the synthesis of a range of chemical products. Its reactivity and functional groups make it a versatile compound for creating various organic compounds with specific applications in different sectors, such as agriculture, materials science, and specialty chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 2387-08-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,3,8 and 7 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 2387-08:
(6*2)+(5*3)+(4*8)+(3*7)+(2*0)+(1*8)=88
88 % 10 = 8
So 2387-08-8 is a valid CAS Registry Number.
InChI:InChI=1/C7H7Cl2N/c1-4-2-5(8)6(9)3-7(4)10/h2-3H,10H2,1H3
2387-08-8Relevant articles and documents
PYRROLOPYRAZINE KINASE INHIBITORS
-
Page/Page column 187; 188, (2013/03/28)
The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.
CYCLIC AMIDINES USEFUL AS NMDA NR2B ANTAGONISTS
-
, (2008/06/13)
The invention encompasses novel compounds of Formula I as well as a method of treating NMDA mediated diseases comprising administration to a patient in need of such treatment a non-toxic amount of a compound of Formula I effective to block the NMDA NR2B r